新闻
AFMD
--
0.00%
--
分析 Affimed 的异常期权活动
Shares of Affimed (NASDAQ:AFMD) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down to $6.77.
Benzinga · 07/13 15:17
不寻常的选项活动洞察:Affimed
On Thursday, shares of Affimed (NASDAQ:AFMD) saw unusual options activity. After the option alert, the stock price moved down to $7.49.
Benzinga · 07/01 15:42
The Daily Biotech Pulse:Spero 对辉瑞投资的飙升,FDA 对爵士乐的点头,Orchard 签署许可协议,Acumen Pharma 首次亮相
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30)
Benzinga · 07/01 12:06
2021 年第一季度财务业绩简报
reuters.com · 07/01 10:36
预计 2021 年 7 月 1 日的收益
  Companies Reporting Before The Bell • Simply Good Foods (NASDAQ:SMPL) is projected to report quarterly earnings at $0.29 per share on revenue of $244.29 million.
Benzinga · 07/01 08:08
Affimed 收益预览
Affimed (NASDAQ:AFMD) announces its next round of earnings this Thursday, July 01. Here is Benzinga's look at Affimed's Q1 earnings report.
Benzinga · 06/30 15:59
生物技术的未来一周:Mediwound、Provention FDA 决定、IPO、待定临床读数聚焦
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.
Benzinga · 06/27 16:55
Affimed的AFM13与NK细胞结合显示出更好的肿瘤识别能力,在临床前研究中具有杀伤力
Benzinga · 05/14 13:30
参股数量贸易商散布题为“具有双特异性抗体的NK细胞显示出对淋巴瘤细胞的活性”的报告
https://www.mdanderson.org/newsroom/nk-cells-bispecific-antibody-show-activity-against-lymphoma-cells.h00-159460845.html
Benzinga · 05/13 20:00
Leerink Partners仍保留买进(AFMD)的交易
In a report issued on April 27, Daina Graybosch from Leerink Partners maintained a Buy rating on Affimed (AFMD). The company's shares closed last
SmarterAnalyst · 04/29 08:53
每日生物技术脉动:礼来公司,诺华制药公司第一季度追踪估计,应用遗传学专业执行人员离职,学者岩石专利奖,Aldeyra数据读取
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26)
Benzinga · 04/27 11:41
涉案(AFMD)进入超买地区
Zacks.com · 04/27 10:58
一季报超预期,电信巨头AT&T逆市创新高!
富途牛牛 · 04/23 12:22
天然杀伤细胞和其他有望治疗的癌症
Barrons.com · 04/15 17:29
每日生物技术动向:默克搁置2 COVID-19研究,Bristol-Myers Squibb获得欧洲法规提名,InspireMD的逆向分裂
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14)
Benzinga · 04/15 11:49
XOMA新增了三项特许权使用费资产
MT Newswires · 04/15 10:59
Afimed报告20财年亏损;收入下降
MT Newswires · 04/15 09:15
Leerink Partners认为受害人(AFMD)仍有增长空间
In a report issued on April 9, Daina Graybosch from Leerink Partners reiterated a Buy rating on Affimed (AFMD). The company's shares closed last Monday at
SmarterAnalyst · 04/13 13:26
每日生物技术脉动:阿玛琳的领导权过渡,强生公司的疫苗受挫,美国食品药品管理局提名罗氏哮喘药物的标签扩展
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 04/13 12:16
简要概述在Aacr虚拟年会I上,其先天细胞吞噬Afm24作为针对实体瘤的Egfr靶向疗法的潜力,如单药疗法以及与过继性Nk细胞转移的结合
reuters.com · 04/12 11:33
微牛提供丰富的实时AFMD股票新闻,让你可以通过多个平台了解AFMD股票行情最新动态,这些免费的Affimed新闻可以帮助你做出明智投资。
AFMD 简况
Affimed NV是一家临床阶段的生物制药公司,致力于发现和开发癌症免疫疗法。该公司开发免疫肿瘤领域的候选产品,代表一种旨在利用人体自身免疫系统对抗肿瘤细胞的癌症研究方法。其产品包括AFM13、AFM13+过继性NK细胞、AFM13+抗PD-1、AMF24、AMF26、AMF28和AMF32。该公司正在将患者纳入针对AFM13的CD30阳性复发/难治性外周T细胞淋巴瘤的定向研究,以及AFM24治疗晚期EGFR表达实体瘤的1/2a剂量递增/扩展研究。其临床前候选产品包括用于治疗多发性骨髓瘤的AMF26,以及用于治疗多个肿瘤靶标的AMF28和AMF32。此外,该公司与Genentech合作,开发和商业化可治疗多种癌症的候选产品。